ADAR1 Capital Management Discloses 9.9% Stake in Grace Therapeutics, Inc. (GRCE) via Warrants

On May 15, 2026, ADAR1 Capital Management, LLC, along with its affiliates ADAR1 Capital Management GP, LLC and Daniel Schneeberger, filed a Schedule 13G/A regarding their holdings in Grace Therapeutics, Inc. (GRCE). The filing reports a beneficial ownership of 1,717,426 shares of common stock, representing a 9.9% ownership stake in the company. This position primarily consists of shares underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. The reporting persons have specified that their ownership is subject to a 9.99% beneficial ownership limitation, effectively excluding an additional 412,288 shares that would otherwise be exercisable. Daniel Schneeberger serves as the control person for these entities. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This amendment reflects a significant increase from the previously reported 0.0% ownership.